Abciximab reduces mortality in diabetics following percutaneous coronary intervention. (Q54057930)

24 May 2018

title

Abciximab reduces mortality in diabetics following percutaneous coronary intervention. (English)

1 reference

24 May 2018

author

Eric J. Topol

6

1 reference

24 May 2018

A Michael Lincoff

3

object named as

A M Lincoff

1 reference

24 May 2018

5

S G Ellis

1 reference

24 May 2018

D L Bhatt

1

1 reference

24 May 2018

S P Marso

2

1 reference

24 May 2018

K E Wolski

4

1 reference

24 May 2018

language of work or name

English

0 references

publication date

1 March 2000

1 reference

24 May 2018

Journal of the American College of Cardiology

published in

1 reference

24 May 2018

volume

35

1 reference

24 May 2018

issue

4

1 reference

24 May 2018

page(s)

922-928

1 reference

24 May 2018

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Comparison of factors associated with 30-day mortality after coronary artery bypass grafting in patients with versus without diabetes mellitus. Israeli Coronary Artery Bypass (ISCAB) Study Consortium

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

One-year outcomes of diabetic versus nondiabetic patients with non-Q-wave acute myocardial infarction treated with percutaneous transluminal coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Relationship Between Diabetes Mellitus and Long-term Survival After Coronary Bypass and Angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Problem of Angioplasty in Diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Diabetes and decline in heart disease mortality in US adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

The changing face of macrovascular disease in non-insulin-dependent diabetes mellitus: an epidemic in progress

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

A cross-sectional evaluation of spontaneous platelet aggregation in relation to complications in patients with type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Heart disease in diabetes mellitus: A challenge for early diagnosis and intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Activated platelets in subjects at increased risk of IDDM. DENIS Study Group. Deutsche Nikotinamid Interventionsstudie

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Retinopathy Identifies Marked Restriction of Coronary Flow Reserve in Patients With Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Reduced Myocardial Flow Reserve in Non–Insulin-Dependent Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Induction of Hyperinsulinemia Combined With Hyperglycemia and Hypertriglyceridemia Increases Plasminogen Activator Inhibitor 1 in Blood in Normal Human Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Effect of past and concurrent body mass index on prevalence of glucose intolerance and type 2 (non-insulin-dependent) diabetes and on insulin response. The Israel study of glucose intolerance, obesity and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

The optimal mode of coronary revascularization for diabetics. A risk-adjusted long-term study comparing coronary angioplasty and coronary bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Aypass Angioplasty Revascularization Investigation (BARI)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

The interventional cardiologist and the diabetic patient. Have we pushed the envelope too far or not far enough?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Importance of considering atherosclerosis progression when choosing a coronary revascularization strategy: the diabetes-percutaneous transluminal coronary angioplasty dilemma

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus: a clue to the explanation of the results of the BARI study. Balloon Angioplasty Revascularization Investigation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Role of Adhesion Molecules in Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Platelet-Leukocyte-Cross-Talk in Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (alphavbeta3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

The sulfonylurea controversy: more questions from the heart

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900650-6

7 January 2021

10.1016/S0735-1097(99)00650-6

Identifiers

DOI

1 reference

24 May 2018

1 reference

24 May 2018